Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 6/20 | 0.98 |
| ▸ | CRACR2A | Q9BSW2 | 11/20 | 0.68 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668135 | 0.99 | ORAI1 (1.00) | ORAI1CRACR2ACCNE1CDK2CDK5 | |
| SCHEMBL30096570 | 0.99 | ORAI1 (1.00) | ORAI1CRACR2ACCNE1CDK2CDK5 | |
| SCHEMBL31174925 | 0.95 | ORAI1 (0.92) | ORAI1CRACR2ACCNE1CDK2CDK5 | |
| Hydrochloric Acid SCHEMBL1890526 | 0.89 | ORAI1 (0.78) | ORAI1CRACR2ACCNE1CDK2CDK5 | |
| Hydrochloric Acid SCHEMBL1667876 | 0.88 | ORAI1 (0.77) | ORAI1CRACR2A | |
| SCHEMBL1668060 | 0.88 | ORAI1 (0.79) | ORAI1CRACR2ACCNE1CDK2CDK5 | |
| Hydrochloric Acid SCHEMBL1670361 | 0.87 | ORAI1 (0.98) | ORAI1CRACR2ACCNE1CDK2CDK5 | |
| SCHEMBL1668158 | 0.87 | ORAI1 (0.78) | ORAI1CRACR2ACCNE1CDK2CDK5 | |
| SCHEMBL16588852 | 0.87 | ORAI1 (0.78) | ORAI1CRACR2A | |
| SCHEMBL1667999 | 0.86 | ORAI1 (1.00) | ORAI1CRACR2ACCNE1CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | claimed |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2019-01-08 | — | — | US | claimed |
| EP-2509974-B1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-11 | — | — | EP | claimed |
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3849552-A1 | COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF | Rhizen Pharmaceuticals AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200281918-A1 | CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL MODULATORS FOR TREATING HEMATOLOGICAL AND SOLID CANCERS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-09-10 | — | — | US | disclosed |
| CN-111629727-A | Calcium release activated calcium channel modulators for the treatment of hematologic tumors and solid cancers | 瑞真药业公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111565719-A | CRAC channel modulators for the treatment of esophageal cancer | 瑞真药业公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200237743-A1 | CRAC CHANNEL MODULATORS FOR TREATING ESOPHAGEAL CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2020-07-30 | — | — | US | disclosed |
| WO-2020053834-A1 | COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-19 | — | — | WO | disclosed |
| CN-110627724-A | Pyrazole derivative calcium release-activated calcium channel modulators and methods of treating non-small cell lung cancer | 理森制药股份公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2019-08-15 | — | — | US | disclosed |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2019-01-08 | — | — | US | disclosed |
| EP-2509974-B1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2015-10-15 | — | — | US | disclosed |
| US-8993612-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2015-03-31 | — | — | US | disclosed |
| EP-2509974-A1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON- SMALL CELL LUNG CANCER | Rhizen Pharmaceuticals S.A. (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | HDAC3 2520/4885ORAI1 1/4885CRACR2A 53/4885 |
| US-20200281918-A1 | CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL MODULATORS FOR TREATING HEMATOLOGICAL AND SOLID CANCERS | ORAI1, CACNA1E, CACNA1C | HDAC3 240/4885ORAI1 1/4885CRACR2A 93/4885 |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | HDAC3 2520/4885ORAI1 1/4885CRACR2A 53/4885 |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | HDAC3 2520/4885ORAI1 1/4885CRACR2A 53/4885 |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | ORAI1, CACNA1E, CACNB2 | HDAC3 2555/4885ORAI1 1/4885CRACR2A 55/4885 |
| US-20200237743-A1 | CRAC CHANNEL MODULATORS FOR TREATING ESOPHAGEAL CANCER | ORAI1, CACNA1E, CACNA1C | HDAC3 249/4885ORAI1 1/4885CRACR2A 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.